IP Library Granted Patent US 11,717,488
Granted Patent B2
US 11,717,488 · App. 17/351,937 · Granted Aug 8, 2023

Particle formation and morphology

Inventors: Paul Brown (Boston, MA); Lyndon Fitzgerald Charles, Jr. (Medford, MA); Chase Spenser Coffman (Newton, MA); Daniel Benjamin Dadon (East Boston, MA); James Ivey (Somerville, MA); Lisa Liu (Somerville, MA); Chaitanya Sudrik (Stoneham, MA)
Assignee: Elektrofi, Inc.
A61K9/51C07K16/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,717,488
App. No.
17/351,937
Granted
Aug 8, 2023
Kind
B2
Abstract

The present disclosure relates to compositions and methods that enable the formation of pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled formation of circular particles having low internal void spaces comprising bioactive therapeutic agents.

Claims (16)

1. A particle comprising at least one antibody or a fragment thereof, an amino acid, a carbohydrate, a salt, and a surfactant, wherein the circularity of the particle is from about 0.80 to about 1.00, and wherein the particle has less than about 10% internal void space, a diameter of about 10 μm to about 50 μm, and greater than about 70% antibody or a fragment thereof by weight.

2. The particle of claim 1 , wherein the particle has less than about 5% internal void space.

3. The particle of claim 1 , wherein the particle has less than about 1% internal void space.

4. The particle of claim 1 , wherein the particle has a diameter of about 20 μm to about 40 μm.

5. The particle of claim 1 , further comprising a pH adjusting agent, a bactericide, or a combination thereof.

6. The particle of claim 1 , wherein the particle has less than about 5% residual moisture by weight.

7. The particle of claim 1 , wherein the particle has less than about 3% residual moisture by weight.

8. The particle of claim 1 , wherein the particle has less than about 1% residual moisture by weight.

9. The particle of claim 1 , wherein the particle has greater than about 80% antibody or a fragment thereof by weight.

10. The particle of claim 1 , wherein the particle has greater than about 90% antibody or a fragment thereof by weight.

11. The particle of claim 1 , wherein the particle has greater than about 95% antibody or a fragment thereof by weight.

12. The particle of claim 1 , comprising: greater than about 90% antibody or fragment thereof by weight, about 4 mg/ml amino acid, about 1 mg/ml carbohydrate, about 0.7 mg/ml salt, and about 0.6 mg/ml surfactant.

13. The particle of claim 1 , wherein the amino acid is L-arginine, histidine, proline, methionine, or a combination thereof.

14. The particle of claim 1 , wherein the carbohydrate is sucrose, trehalose, or a combination thereof.

15. The particle of claim 1 , wherein the salt is sodium chloride.

16. The particle of claim 1 , wherein the surfactant is a polysorbate.

Assignments (2)
CHANGE OF NAME Recorded Feb 2, 2026
From: ELEKTROFI, INC.
To: HALOZYME HYPERCON, INC.
Reel/Frame 073662/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2021
From: BROWN, PAUL; CHARLES, LYNDON FITZGERALD, JR.; COFFMAN, CHASE SPENSER; DADON, DANIEL BENJAMIN; IVEY, JAMES; LIU, LISA; SUDRIK, CHAITANYA
To: ELEKTROFI, INC.
Reel/Frame 056949/0493 →
Continuity (3)
Continuation PCTUS2020015957 · Jan 30, 2020
Provisional Application 62799696 · Jan 31, 2019
Related Publication 20210315827A1 · Oct 14, 2021
Cited By (7)
US 12,263,249 US 12,263,253 US 12,377,050 US 12,433,849 US 12,558,323 US 12,569,445 US 12,600,763